Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain

References

• Martín-PeñaAAguilar-GuisadoMEspigadoICisnerosJMAntifungal combination therapy for invasive aspergillosisClin Infect Dis201459101437144525048847
   PubMed Web of Science ®Google Scholar
• UptonAKirbyKACarpenterPBoeckhMMarrKAInvasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortalityClin Infect Dis200744453154017243056
   PubMed Web of Science ®Google Scholar
• MihuCNKassisCRamosERJiangYHachemRYRaadIIDoes combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?Cancer2010116225290529620665889
   PubMed Web of Science ®Google Scholar
• PaganoLCairaMCandoniAThe epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 studyHaematologica20069181068107516885047
   PubMed Web of Science ®Google Scholar
• Servicio Madrileño de Salud. Order 731/2013 [Updated 2013 April 13]. Available from: http://www.madrid.org/wleg/servlet/Servidor?opcion=VerHtml&nmnorma=8275&cdestado=P#_ftn1Accessed July 6, 2016
   Google Scholar
• Servicio Navarro de Salud-Osasunbidea. Resolution 626/2014 [Updated 2014 June 5]. Available from: http://www.boletinesoficiales.com/documentacion/legislacion/documento/RESOLUCION-626-2014-5-junio-Director-Gerente-Servicio-Navarro-Salud-Osasunbidea-actualizan-tarifas-servicios-prestados,50,20140709,10/Accessed July 6, 2016
   Google Scholar
• OstermannHSolanoCJarqueICost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and SpainBMC Pharmacol Toxicol2014155225253630
   PubMed Web of Science ®Google Scholar
• JarqueIAndreuRSalavertMValue of Aspergillus galactomannan antigen detection in the diagnosis and follow-up of invasive aspergillosis in hematological patientsRev Iberoam Micol2003203116118 Spanish15456368
   PubMedGoogle Scholar
• MarrKASchlammHTHerbrechtRCombination antifungal therapy for invasive aspergillosis: a randomized trialAnn Intern Med20151622818925599346
   PubMed Web of Science ®Google Scholar
• BriggASculpherMClaxtonKDecision Modelling for Health Economic EvaluationOxford, UKOxford University Press2006
   Google Scholar
• US Environmental Protection AgencyEPA/630/R-97/001 Guiding principles for Monte Carlo analysis [Updated 1997 March 1]. Available from: https://www.epa.gov/sites/production/files/2014-11/documents/montecar.pdfAccessed July 6, 2016
   Google Scholar
• US Food Drug AdministrationWhat is a serious adverse event? [Updated 2016 January 2]. Available from: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htmAccessed January 8, 2016
   Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos. Bot Plus 2.0 [Updated 2016 January 26]. Available from: https://botplusweb.portalfarma.com/Accessed June 25, 2016
   Google Scholar
• European Medicines AgencyECALTA summary of product characteristics [Updated 2014 September 10]. Available from: https://www.medicines.org.uk/emc/medicine/22690Accessed July 6, 2016
   Google Scholar
• European Medicines AgencyVFEND summary of product characteristics [Updated 2015 December 24]. Available from: https://www.medicines.org.uk/emc/medicine/10059Accessed July 6, 2016
   Google Scholar
• Ministerio de Sanidad Servicios Sociales e IgualdadTalla y peso medio, según grupo de edad y sexo [Updated 2001 July 13]. Available from: http://www.msssi.gob.es/estadEstudios/estadisticas/inforRecopilaciones/atlas/atlasDatos.htmAccessed July 6, 2016
   Google Scholar
• OjedaBde SandeLMCasadoAMerinoPCasadoMACost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in SpainBr J Cancer20038961002100712966416
   PubMed Web of Science ®Google Scholar
• Martin-IglesiasSEstudio de costes y efectividad de la intervención enfermera en el estreñimiento crónico [Updated 2006 November 24]. Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-el-instituto/fd-organizacion/fd-estructura-directiva/fd-subdireccion-general-servicios-aplicados-formacion-investigacion/fd-centros-unidades/fd-investen-isciii-2/docus/2006_X_encuentro_Investen_Albacete.pdfAccessed July 7, 2016
   Google Scholar
• Llibre-CodinaJMCasado-GómezMASánchez-de la RosaRCost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patientsEnferm Infecc Microbiol Clin200725298107 Spanish17288907
   PubMed Web of Science ®Google Scholar
• Presidente de la Gerencia Regional de Salud. Resolution of July 1, 2008 [Updated 2008 July 1]. Available from: http://www.saludcastil-layleon.es/institucion/es/recopilacion-normativa/asistencia-sanitaria/prestaciones-derechos/resolucion-1-julio-2008-presidente-gerencia-regional-salud-Accessed July 6, 2016
   Google Scholar
• Ministerio de Sanidad Servicios Sociales e IgualdadNorma estatal de los AP GRD V23 por cluster 2009 [Updated 2009 November 6]. Available from: http://www.msps.es/estadEstudios/estadisticas/docs/NormaGRD2009/NORMA_2009_AP_GRD_V23_CLUSTER.xlsAccessed July 6, 2016
   Google Scholar
• HolstensonERingborgALindgrenPPredictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countriesEuropace2011131233020823043
   PubMed Web of Science ®Google Scholar
• IslaDGonzález-RojasNNievesDBrosaMFinnernHWTreatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panelClin Transl Oncol201113746047121775273
   PubMed Web of Science ®Google Scholar
• AsensioABouzaEGrauSRubio-RodríguezDRubio-TerrésCCost of Clostridium difficile associated diarrhea in SpainRev Esp Salud Publica20138712533 Spanish23748655
   PubMed Web of Science ®Google Scholar
• JansenJPMeisJFBlijlevensNMvan’t WoutJWEconomic evaluation of voriconazole in the treatment of invasive aspergillosis in the NetherlandsCurr Med Res Opin200521101535154616238893
   PubMed Web of Science ®Google Scholar
• JansenJPKernWVCornelyOAEconomic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in GermanyValue Health200691122316441520
   PubMed Web of Science ®Google Scholar
• AmentAJHübbenMWVerweijPEEconomic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approachJ Antimicrob Chemother200760238539317561501
   PubMed Web of Science ®Google Scholar
• KruegerKPNelsonACEconomic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studiesClinicoecon Outcomes Res2009200913543
   Google Scholar
• De CockEMiravitllesMGonzález-JuanateyJRAzanza-PereaJRThreshold value of the cost per year of life gained to recommend the adoption of health technologies in Spain: evidence from a literature review [Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura]Pharmacoecon Span Res Artic20074397107
   Google Scholar
• SacristánJAOlivaJDel LlanoJPrietoLPintoJLWhat is an efficient health technology in Spain?Gac Sanit2002164334343 Spanish12113733
   PubMedGoogle Scholar
• Rodriguez-TudelaJLAlastruey-IzquierdoAGagoSBurden of serious fungal infections in SpainClin Microbiol Infect201521218318925658565
   PubMed Web of Science ®Google Scholar
• SchwartzDFlamantRLellouchJClinical TrialsLondon, UKAcademic Press1980
   Google Scholar
• Curran-EverettDMilgromHPost-hoc data analysis: benefits and limitationsCurr Opin Allergy Clin Immunol201313322322423571411
   PubMed Web of Science ®Google Scholar
• Rubio-TerrésCCoboESacristánJAPrietoLDel LlanoJBadiaXAnalysis of uncertainty in the economic assessment of health interventionsMed Clin (Barc)200412217668674 Spanish15153348
   PubMed Web of Science ®Google Scholar
• PaxtonPCurranPJBollenKAKirbyJChenFMonte Carlo experiments: design and implementationStructural Equation Modeling200182287312
   Web of Science ®Google Scholar
• Martín-PeñaAGil-NavarroMVAguilar-GuisadoMCost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropeniaAntimicrob Agents Chemother201357104664467223856767
   PubMed Web of Science ®Google Scholar
• FungMKimJMartyFMSchwarzingerMKooSMeta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropeniaPLoS One20151011e014093026554923
   PubMed Web of Science ®Google Scholar
• PeiróSGómezGRejasJGuadarramaIBlancaABLength of stay and antifungal treatments costs in patients with systemic mycosis: description and associated factorsValue Health200256564
   Web of Science ®Google Scholar
• Grau CerratoSMateu-de AntonioJSoto AlvarezJEconomic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosisFarm Hosp2005291510 Spanish15773796
   PubMedGoogle Scholar